表紙
市場調查報告書

市場焦點:特發性肺纖維化(IPF)

Market Spotlight: Idiopathic pulmonary fibrosis (IPF)

出版商 Datamonitor Healthcare 商品編碼 939987
出版日期 內容資訊 英文 42 Pages
商品交期: 最快1-2個工作天內
價格
市場焦點:特發性肺纖維化(IPF) Market Spotlight: Idiopathic pulmonary fibrosis (IPF)
出版日期: 2020年04月21日內容資訊: 英文 42 Pages
簡介

本報告提供全球突發性肺纖維化的市場調查,提供疾病的背景,治療方法,流行病學,上市的醫藥品,開發平台上的醫藥品,藥事法規方面的重要動向,授權與資產收購,本源專利,商機,臨床試驗狀況等資訊,再加上分析師和意見領袖的意見等資訊。

目錄

概要

主要調查結果

疾病的背景

  • 定義
  • 患者的分類
  • 症狀
  • 危險因素
  • 診斷

治療方法

  • 藥理學性治療
  • 非藥理學性治療

流行病學

上市的醫藥品

開發平台上的醫藥品

最新趨勢分析師的意見

  • GLPG1690(2019年7月14日)
  • INOpulse(2019年1月7日)

今後主要的動向

法規方面主要的動向

  • Promedior的PRM-151引領IPF藥物開發競爭

成功的可能性

許可和資產收購協議

  • Roche在Promedior中預投資3.9億美元
  • Boehringer公司採用Bridge的Autotaxin抑製劑增強IPF治療藥物組合
  • Gilead在Galapagos投資50億美元

本源專利

商機

臨床試驗狀況

  • 各階段的臨床試驗贊助者
  • 各期的臨床試驗贊助者
  • 最新趨勢

參考文獻

  • 處方藥相關資訊

附錄

目錄
Product Code: DMKC0205920

This Market Spotlight report covers the Idiopathic Pulmonary Fibrosis market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, 10-year disease incidence and prevalence forecasts, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways:

Datamonitor Healthcare estimates that in 2019, there were 187,040 incident and 714,260 prevalent cases of idiopathic pulmonary fibrosis (IPF) in adults aged 20 years and older worldwide, and forecasts that number to increase to 209,960 incident cases and 798,760 prevalent cases by 2028. Roche's Esbriet and Boehringer's Ofev are the only approved drugs for IPF. These drugs are administered via the oral route. The largest proportion of industry-sponsored drugs in active clinical development for IPF are in Phase II, with two drugs in Phase III.

  • Therapies in development for IPF focus on a wide variety of targets. The majority of pipeline drugs in development are administered via the oral route.
  • High-impact upcoming events in the IPF space comprise topline Phase IIa trial results for PLN-74809, topline Phase II trial results for GLPG1205, and topline Phase III trial results for GLPG1690 and pamrevlumab.
  • The overall likelihood of approval of a Phase I respiratory-other asset is 10.6%, and the average probability a drug advances from Phase III is 57.1%. Drugs, on average, take 11.2 years from Phase I to approval, compared to 9.5 years in the overall respiratory space.
  • There have been 18 licensing and asset acquisition deals involving IPF drugs during 2015-20. The $5,375m global research and development collaboration agreement signed in 2019 between Gilead and Galapagos, pursuant to which Gilead gained access to Galapagos's drug discovery platform and current and future pipeline outside of Europe, was the largest deal.
  • The distribution of clinical trials across Phase I-IV indicates that the majority of trials for IPF have been in the early and midphases of development, with 66% of trials in Phase I-II, and 34% in Phase III-IV.
  • The US has a substantial lead in the number of IPF clinical trials globally. The UK leads the major European markets, while Israel has the top spot in Asia.
  • Clinical trial activity in the IPF space is dominated by completed trials. Roche has the highest number of completed clinical trials for IPF, with 18 trials.
  • Roche leads the industry sponsors with the highest overall number of clinical trials for IPF, followed by Boehringer Ingelheim.

TABLE OF CONTENTS

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

  • Disease definition
  • Patient segmentation
  • Symptoms
  • Risk factors
  • Diagnosis

TREATMENT

  • Pharmacologic treatment
  • Non-pharmacologic treatments

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

  • GLPG1690 for IPF (July 14, 2019)
  • INOpulse for IPF (January 7, 2019)

KEY UPCOMING EVENTS

KEY REGULATORY EVENTS

  • BTD Makes Promedior's PRM-151 Stand Out In IPF Race; Will Bristol Bite?

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

  • Roche Paying $390m Up Front For Fibrosis-Fighting Promedior
  • Boehringer Further Buoys IPF Portfolio With Bridge's Autotaxin Inhibitor
  • $5bn Galapagos Deal Won't Be Last For Gilead, Says O'Day

PARENT PATENTS

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase
  • Recent events

BIBLIOGRAPHY

  • Prescription information

APPENDIX

LIST OF FIGURES

  • Figure 1: Trends in incident cases of IPF, 2019-28
  • Figure 2: Trends in prevalent cases of IPF, 2019-28
  • Figure 3: Overview of pipeline drugs for IPF in the US
  • Figure 4: Pipeline drugs for IPF, by company
  • Figure 5: Pipeline drugs for IPF, by drug type
  • Figure 6: Pipeline drugs for IPF, by classification
  • Figure 7: INOpulse for IPF (January 7, 2019): Phase II/III - iNO-PF
  • Figure 8: Key upcoming events in IPF
  • Figure 9: Probability of success in the IPF pipeline
  • Figure 10: Licensing and asset acquisition deals in IPF, 2015-20
  • Figure 11: Parent patents in IPF
  • Figure 12: Clinical trials in IPF
  • Figure 13: Top 10 drugs for clinical trials in IPF
  • Figure 14: Top 10 companies for clinical trials in IPF
  • Figure 15: Trial locations in IPF
  • Figure 16: IPF trials status
  • Figure 17: IPF trials sponsors, by phase

LIST OF TABLES

  • Table 1: Incident cases of IPF, 2019-28
  • Table 2: Prevalent cases of IPF, 2019-28
  • Table 3: Marketed drugs for IPF
  • Table 4: Pipeline drugs for IPF in the US
  • Table 5: GLPG1690 for IPF (July 14, 2019)
  • Table 6: INOpulse for IPF (January 7, 2019)
  • Table 7: Historical global sales, by drug ($m), 2014-18
  • Table 8: Forecasted global sales, by drug ($m), 2020-24